Search

Your search keyword '"Natalia L. Vypova"' showing total 3 results
Start Over Author "Natalia L. Vypova"
3 results on '"Natalia L. Vypova"'

1. Repurposing of Rutan showed effective treatment for COVID-19 disease

Author

Shavkat I. Salikhov, Ibrokhim Y. Abdurakhmonov, Yuliya I. Oshchepkova, Jamolitdin F. Ziyavitdinov, Nodir Sh. Berdiev, Haji Akber Aisa, Jingshan Shen, Yechun Xu, H. Eric Xu, Xiangrui Jiang, Leike Zhang, Natalia L. Vypova, Dilshod Sh. Allaberganov, Nigora A. Tagayalieva, Erkin I. Musabaev, Gulnara A. Ibadova, Ilxom B. Rajabov, and Lyubov M. Lokteva

Subjects
COVID-19, SARS-CoV-2, 3CLpro, RdRp, Rhus coriaria, Rutan, Medicine (General), R5-920
Abstract

Previously, from the tannic sumac plant (Rhus coriaria), we developed the Rutan 25 mg oral drug tablets with antiviral activity against influenza A and B viruses, adenoviruses, paramyxoviruses, herpes virus, and cytomegalovirus. Here, our re-purposing study demonstrated that Rutan at 25, 50, and 100 mg/kg provided a very effective and safe treatment for COVID-19 infection, simultaneously inhibiting two vital enzyme systems of the SARS-CoV-2 virus: 3C-like proteinase (3CLpro) and RNA-dependent RNA polymerase (RdRp). There was no drug accumulation in experimental animals’ organs and tissues. A clinical study demonstrated a statistically significant decrease in the C-reactive protein and a reduction of the viremia period. In patients receiving Rutan 25 mg (children) and 100 mg (adults), the frequency of post-COVID-19 manifestations was significantly less than in the control groups not treated with Rutan tablets. Rutan, having antiviral activity, can provide safe treatment and prevention of COVID-19 in adults and children.Clinical Trial RegistrationClinicalTrials.gov, ID NCT05862883.

Published
2023
Full Text
View/download PDF

3. Study of the antitumor activity of the drug Dekoglitz on two tumors and some aspects of its mechanism of action

Author

Natalia L. Vypova, Adil Ahmedovich Ibragimov, Jamilya Sh. Polatova, Saida S. Saidhodjaeva, Faizullo Saifyllaevich Salihov, Nigora Alimuhamedovna Agzamova, Zulfiya Mahmudovna Enikeeva, Dilbar A. Kadirova, Otabek D. Tuychiev, Arzayim Ch. Abdirova, and Noroj R. Kholturaeva

Subjects
Drug, Antitumor activity, business.industry, media_common.quotation_subject, Pharmacology, medicine.disease, On cells, Mechanism of action, medicine, Sarcoma, Remission rate, medicine.symptom, Fragmentation (cell biology), business, Etoposide, media_common, medicine.drug
Abstract

Aim: Evaluation of the antitumor activity of the new drug Dekoglitz in animals with tumor strains of Sarcoma 45 in comparison with the drug dekocin, from which it was obtained, as well as with 5-fluorouracil and etoposide, and on ovarian tumors (OT) in comparison with the drug dekocin and identification of the effect of Dekoglitz on NA synthesis and internucleosomal DNA degradation. Methods: The study of preparations was carried out on 68 outbred rats with transplanted C-45 and OT tumors. The alkylating effect of the drugs was studied on cells tumor of Sarcoma 180. Results: The antitumor activity of dekoglitz on Sarcoma 45 was high, about 98/96%, with a remission rate of 80%. Its effect was 28-24% higher than that of dekocin. On OT, the effect of decoglitz with intraperitoneal administration reached 89/76% with a remission rate of 40%, with oral administration 96/86% with a remission rate of 60%. Conclusion: The study of the new drug Dekoglitz on animals with a tumor of Sarcoma 45 revealed its higher activity (by 20-27%) in comparison with the original Dekocin, 5-fluorouracil and etoposide with a lower level of side effects. On OT, the effect of Dekoglitz was 35-40% higher, especially after oral administration. Apparently, the great ability to suppress the synthesis of NA and carry out internucleosomal degradation and fragmentation of tumor DNA by the new drugs dekoglitz explains its antitumor efficacy, which is greater than that of Dekocin (K-18) in experiments on tumors.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results